Palisade Bio Reports Year End 2023 Financial Results and Provides Corporate Update
27. März 2024 08:00 ET
|
Palisade Bio, Inc.
– Rapid advancement of PALI-2108 towards Phase 1 clinical study for the treatment of moderate-to-severe ulcerative colitis; On track to commence Phase 1 before year end – Formation of Clinical...
Three High Profile Publications Support the Potential of Protagenic Therapeutics’s Synthetic TCAP to Treat Stress-Related Psychological Disorders
11. Juni 2018 10:15 ET
|
Protagenic Therapeutics, Inc.
Ancient, central role of brain peptide TCAP in maintenance of brain health elucidated in publications in Cell, Nature Communications, and the Journal of Neuro-endocrinology NEW YORK,...